Drug Trial Radar · NCT04606446
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Nov 16, 2020
Primary completion
Aug 27, 2029
Study completion Aug 27, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents
Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer
- Locally Advanced or Metastatic Castration-resistant Prostate Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
PF-07248144Drug
KAT6 Inhibitor
FulvestrantDrug
Endocrine Therapy
LetrozoleDrug
Endocrine Therapy
PalbociclibDrug
CDK4/6 Inhibitor
PF-07220060Drug
CDK4 inhibitor
PF-07850327, ARV-471, vepdegestrantDrug
PROTAC (PROteolysis Targeting Chimera) ER degrader
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities in the Dose Escalation Arms.Time frame: Up to 29 days
- Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms.Time frame: Up to 24 months
- Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms.Time frame: Up to 24 months
- Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion ArmsTime frame: Up to 24 months
- Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion ArmsTime frame: Up to 24 months
Locations
43 sites in 5 countries. Site status is shown where the registry gives one.
HonorHealth
Scottsdale, Arizona · Terminated
Cedars-Sinai Cancer at Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UCSF Medical Center at Mission Bay
San Francisco, California · Recruiting
Smilow Cancer Hospital at Yale - New Haven
New Haven, Connecticut · Recruiting
Yale-New Haven Hospital- Yale Cancer Center
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Holy Cross Hospital
Fort Lauderdale, Florida · Terminated
St. Elizabeth Healthcare
Edgewood, Kentucky · Recruiting
University Medical Center, lnc.:DBA University of Louisville Hospital
Louisville, Kentucky · Recruiting
University of Louisville
Louisville, Kentucky · Recruiting
UofL Health Brown Cancer Center
Louisville, Kentucky · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
MD Anderson The Woodlands
Conroe, Texas · Recruiting
The University of Texas M. D. Anderson Cancer Center
Houston, Texas · Recruiting
U.T. MD Anderson Cancer Center
Houston, Texas · Recruiting
MD Anderson West Houston
Houston, Texas · Recruiting
MD Anderson League City
League City, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
MD Anderson
Sugar Land, Texas · Recruiting
Swedish Cancer Institute
Seattle, Washington · Recruiting
Swedish Medical Center
Seattle, Washington · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Terminated
Cancer Research South Australia
Adelaide, South Australia, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
Western Health-Sunshine & Footscray Hospitals
St Albans, Victoria, Australia · Recruiting
St. John of God Subiaco Hospital
Subiaco, Western Australia, Australia · Recruiting
Beijing Cancer hospital
Beijing, Beijing Municipality, China · Recruiting
SUN Yat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Jilin Province Tumor Hospital
Changchun, Jilin, China · Recruiting
Jilin Province Tumor Hospital
Changchun, Jilin, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Recruiting
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
Kanagawa cancer center
Yokohama, Kanagawa, Japan · Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], South Korea · Recruiting
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.